

ULTRALIFE CORP  
Form 8-K  
March 18, 2019  
**UNITED  
STATES  
SECURITIES  
AND  
EXCHANGE  
COMMISSION**  
Washington,  
D.C. 20549

**FORM 8-K**

**CURRENT  
REPORT**

**Pursuant to  
Section 13 or  
15(d) of the  
Securities  
Exchange Act of  
1934**

**March 14, 2019**  
Date of Report  
(Date of earliest  
event reported)

**ULTRALIFE  
CORPORATION**  
(Exact name of  
registrant as  
specified in its  
charter)

<b>Delaware</b>	<b>000-20852</b>	<b>16-1387013</b>
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**14513**

**2000**

**Technology  
Parkway,  
Newark,  
New York**

(Address of  
principal  
executive (Zip Code)  
offices)

**(315) 332-7100**

(Registrant's  
telephone number,  
including area code)

Check the  
appropriate box  
below if the Form  
8-K filing is  
intended to  
simultaneously  
satisfy the filing  
obligation of the  
registrant under any  
of the following  
provisions (see  
General Instruction  
A.2. below):

Written  
communications  
pursuant to Rule  
425 under the  
Securities Act (17  
CFR 230.425)

Soliciting  
material pursuant to  
Rule 14a-12 under  
the Exchange Act  
(17 CFR  
240.14a-12)

Pre-commencement  
communications  
pursuant to Rule  
14d-2(b) under the

Exchange Act (17  
CFR 240.14d-2(b))

]  
Pre-commencement  
communications  
pursuant to Rule  
13e-4(c) under the  
Exchange Act (17  
CFR 240.13e-4(c))

Indicate by check  
mark whether the  
registrant is an  
emerging growth  
company as defined  
in Rule 405 of the  
Securities Act of  
1933 or Rule 12b-2  
of the Securities  
Exchange Act of  
1934.  ]

Emerging Growth  
Company  ]

If an emerging  
growth company,  
indicate by check  
mark if the  
registrant has  
elected not to use  
the extended  
transition period for  
complying with any  
new or revised  
financial accounting  
standards provided  
pursuant to Section  
13(a) of the  
Exchange Act.  ]

**Item 8.01 Other Events**

As previously disclosed, on October 31, 2018, Ultralife Corporation's Board of Directors approved a share repurchase program that became effective on November 1, 2018. On March 14, 2019, the Company executed a written trading plan, which will become effective on March 21, 2019, under Rule 10b5-1 of the Securities and Exchange Act of 1934, as amended. The Company may utilize this plan to make purchases of its common stock through May 3, 2019, covering a period during which it would otherwise be subject to a self-imposed trading blackout. Repurchases under the previously announced repurchase plan and the trading plan are subject to the Securities and Exchange Commission's regulations as well as certain price, market, volume and timing constraints specified in the plans.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 18, 2019      **ULTRALIFE Corporation**

By: /s/ Philip A. Fain  
Philip A. Fain  
Chief Financial Officer and Treasurer